United States v. Victor Reza-Ramos , 644 F. App'x 745 ( 2016 )


Menu:
  •                            NOT FOR PUBLICATION                             FILED
    UNITED STATES COURT OF APPEALS                         MAR 09 2016
    MOLLY C. DWYER, CLERK
    FOR THE NINTH CIRCUIT                        U.S. COURT OF APPEALS
    UNITED STATES OF AMERICA,                        No. 11-10029
    Plaintiff - Appellee,              D.C. No. 4:06-cr-01142-FRZ-
    GEE-1
    v.
    VICTOR MANUEL REZA-RAMOS,                        MEMORANDUM*
    Defendant - Appellant.
    Appeal from the United States District Court
    for the District of Arizona
    Frank R. Zapata, Senior District Judge, Presiding
    Argued and Submitted March 11, 2013
    Submission Vacated November 25, 2013
    Resubmitted March 2, 2016
    San Francisco, California
    Before: WALLACE, McKEOWN, and IKUTA, Circuit Judges.
    *
    This disposition is not appropriate for publication and is not precedent
    except as provided by 9th Cir. R. 36-3.
    Victor Manuel Reza-Ramos appeals from his conviction for first degree
    murder under 
    18 U.S.C. § 1111
    . We have jurisdiction to review the district court’s
    final judgment under 
    28 U.S.C. § 1291.1
    The district court did not abuse its discretion in admitting Dr. David
    Cassidy’s testimony regarding his DNA analysis. See United States v. Chischilly,
    
    30 F.3d 1144
    , 1152 (9th Cir. 1994), overruled on other grounds by United States v.
    Preston, 
    751 F.3d 1008
     (9th Cir. 2014) (en banc). The test of reliability
    established by Daubert v. Merrell Dow Pharm., Inc., 
    509 U.S. 579
     (1993) is
    “flexible,” see United States v. Mendoza-Paz, 
    286 F.3d 1104
    , 1112 (9th Cir. 2002),
    and the district court could reasonably conclude that Dr. Cassidy’s explanation of
    his methodology was adequate to establish that it was scientifically valid and
    reliable, see Lust ex. rel. Lust v. Merrell Dow Pharm., Inc., 
    89 F.3d 594
    , 597–98
    (9th Cir. 1996), and based on research conducted independent of the litigation, see
    Daubert v. Merrell Dow Pham., Inc., 
    43 F.3d 1311
    , 1317–18 (9th Cir. 1995).
    The district court did not abuse its discretion in limiting the scope of Reza-
    Ramos’s questioning of Dr. Cassidy regarding whether he had used a specified
    DNA testing method. See United States v. Larson, 
    495 F.3d 1094
    , 1101 (9th Cir.
    1
    We address Reza-Ramos’s remaining arguments in an opinion filed
    concurrently with this disposition. United States v. Reza-Ramos, ___ F.3d ____
    (2016).
    2
    2007) (en banc). Reza-Ramos was permitted to question Dr. Cassidy regarding the
    reliability of his methods, including the sample size used, and so had an
    “opportunity for effective cross-examination.” Delaware v. Van Arsdall, 
    475 U.S. 673
    , 679 (1986). Accordingly, the district court’s ruling did not deny Reza-Ramos
    “the right of effective cross-examination.” Davis v. Alaska, 
    415 U.S. 308
    , 318
    (1974).
    The district court did not abuse its discretion in admitting Dr. Cassidy’s
    testimony about his statistical interpretations of the DNA data. The court could
    reasonably conclude that Dr. Cassidy’s testimony was based on sufficient facts and
    was the product of reliable principles and methods, see Fed. R. Evid. 702, and that
    its probative value was not substantially outweighed by any prejudicial effect, see
    Fed. R. Evid. 403. Further, Dr. Cassidy’s testimony at trial avoided equating “the
    random-match probability” with “the probability that the defendant was not the
    source of the DNA sample,” see McDaniel v. Brown, 
    558 U.S. 120
    , 128 (2010),
    and did not otherwise misstate the probative value of the DNA evidence.
    The prosecutor’s statements during closing arguments did not violate Reza-
    Ramos’s right to due process because they did not “so infect[] the trial with
    unfairness as to make the resulting conviction a denial of due process.” Darden v.
    Wainwright, 
    477 U.S. 168
    , 181 (1986) (internal quotations and citations omitted).
    3
    Although the prosecutor committed the “prosecutor’s fallacy” in explaining the
    DNA evidence in closing argument, the statement did not materially misstate the
    probative value of the DNA evidence, and the evidence of Reza-Ramos’s guilt was
    overwhelming even apart from DNA evidence. Accordingly, there was no
    reasonable probability that the error affected the outcome of the trial. United
    States v. Marcus, 
    560 U.S. 258
    , 262 (2010). For the same reason, we reject Reza-
    Ramos’s challenge to other statements in the prosecutor’s closing argument, which
    either were not errors at all or were harmless in light of the overwhelming evidence
    of guilt.
    The district court did not abuse its discretion in admitting evidence of Reza-
    Ramos’s two prior arrests related to his illegal border crossings. The evidence was
    admissible to prove Reza-Ramos’s alienage and opportunity to commit the crime,
    see Fed. R. Evid. 404(b); see also United States v. Vizcarra-Martinez, 
    66 F.3d 1006
    , 1012–13 (9th Cir. 1995), and was admissible even though the government
    could have adduced other evidence to prove the same matters, Old Chief v. United
    States, 
    519 U.S. 172
    , 179 (1997).
    Reza-Ramos’s argument that 
    18 U.S.C. § 1111
    (b)’s mandatory sentence of
    life imprisonment is unconstitutional is foreclosed by United States v. LaFleur, 
    971 F.2d 200
    , 211–13 (9th Cir. 1991).
    4
    Finally, we reject Reza-Ramos’s argument that cumulative errors at trial
    require reversal, because any errors did not render the resulting criminal trial
    fundamentally unfair. See Parle v. Runnels, 
    505 F.3d 922
    , 927 (9th Cir. 2007).
    AFFIRMED.
    5